Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977119 · ClinicalTrials.gov registry record
Investigation of Genetic Determinants of Capecitabine Toxicity
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 240
- Enrollment target
NCT00977119: Completed study, sponsored by University of Chicago.
NCT00977119 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 240 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00977119 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 240 participants
- Enrollment target
Study Summary
The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia). Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, the frequency of polymorphisms and differences in drug metabolism.
Interventions
- OTHER Side-effect questionnaires
- OTHER research blood samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2009-11-23 |
| Est. Completion | 2021-06-21 |
What the finished NCT00977119 record still lists
NCT00977119 is an observational study that tracks outcomes without assigning an intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Side-effect questionnaires is the first listed.
NCT00977119 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00977119 about?
NCT00977119 is a clinical study titled "Investigation of Genetic Determinants of Capecitabine Toxicity". The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia). Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, ...
What is the current status of trial NCT00977119?
This trial is currently completed. The enrollment target is 240 participants. The study started on 2009-11-23. Estimated completion is 2021-06-21.
What interventions are being tested in trial NCT00977119?
The interventions under investigation include: Side-effect questionnaires (OTHER), research blood samples (OTHER).
Who is sponsoring clinical trial NCT00977119?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI